摘要
目的探讨奈达铂、表柔比星及异环磷酰胺联合治疗复发性卵巢癌的疗效和安全性。方法16例复发性卵巢癌患者采用奈达铂150mg＋0．9％氯化钠注射液500ml静脉滴注，第1天；表柔比星40mg＋5％葡萄糖注射液50ml，静脉滴注，第1～2天；异环磷酰胺2．0g＋0．9％氯化钠注射液500ml，静脉滴注，第1—5天。观察临床治疗效果及不良反应发生情况。结果16例复发性卵巢癌患者经治疗后，完全缓解1例，部分缓解6例，稳定7例，进展2例，总有效率43．75％（7／16）。主要不良反应为骨髓抑制及胃肠道反应。结论奈达铂、表柔比星及异环磷酰胺联合治疗复发性卵巢癌疗效肯定，不良反应可耐受，值得临床推广。
Objective To investigate the treatment effects and safety of ifosfamide, nedaplatin with pharmorubicin in relapsed ovarian carcinoma. Methods Sixteen relapsed ovarian carcinoma patients received nedaplatin 150mg in 0. 9% sodium chloride 500ml dl, intravenously; pharmorubicin 40mg in 5% glucose 50 ml dl-2, intrave- nously;and ifosfamide 2.0g in 0. 9% sodium chloride 500ml dl-5 ,intravenously. And the treatment effects and side effects were investigated. Results Of the sixteen patients, one had a complete response, six had a partial response, seven had stable disease,and two had progressive disease. The overall response rate was 43.75% （7/16）. The major side effects were bone marrow suppression and gastrointestinal reaction. Conclusion Combination of ifosfamide, nedaplatin and pharmorubicin were very effective in relapsed ovarian carcinoma and the side effects were tolerable. Therefore the regimen is worth promoting in the clinical application.
出处
《中国基层医药》
CAS
2010年第21期2913-2914,共2页
Chinese Journal of Primary Medicine and Pharmacy
